Discipline + disruption
In the field of cancer research, our approach to building strategies is novel: make disciplined disruptions to the status quo. Our business expertise and pharmaceutical backgrounds allow us to innovate on how things are typically done, making progressive disruptions that improve efficiency, streamline communication and accelerate results. We work urgently to develop collaborative models that accelerate discoveries and improve patient lives. Crucially, we synthesize our plans to be clear-cut and accessible to all involved in pursuit of exemplary execution. We take a cutting-edge approach in order to find a cure for every patient.
Patients are our priority
As we accelerate toward a cure, our goal is to increase survival and improve multiple myeloma patients’ lives. We prioritize patients — bringing breakthrough treatments to the pipeline, starting new clinical trials with the best partners and leveraging our relationships to drive impact. Together with our partners we have the ability to set a strategy, align incentives and lead the way in answering these critical questions from myeloma patients.